Drug intelligence / Profile preview

abobotulinumtoxinA + triamcinolone acetonide

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Injection

Overview

A combination therapy consisting of abobotulinumtoxinA (Dysport), a botulinum toxin type A that blocks acetylcholine release, and triamcinolone acetonide, a corticosteroid with anti-inflammatory properties. This combination has demonstrated synergistic effects in treating pathologic scars and associated symptoms, particularly scar-related itching, with enhanced efficacy compared to triamcinolone alone.

Brand names: Dysport + Triamcinolone acetonide
Other names: Botulinum toxin type A + Triamcinolone acetonideBTA + TCA

Targets

GR (Glucocorticoid receptor)SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on abobotulinumtoxinA + triamcinolone acetonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abobotulinumtoxinA + triamcinolone acetonide.

Explore the full profile